- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Hilary Tindle Discusses Use of the Nicotine Metabolite Ratio in Clinical Care
Hilary Tindle, MD, MPH, associate professor of medicine, at Vanderbilt University, discusses how the nicotine metabolite ratio (NMR) can help inform doctors and patients on choosing the optimal treatment for quitting smoking.
Although not a standard of care, the nicotine metabolite ratio (NMR) helps doctors and patients in a clinical care setting jointly make a decision on the best treatment approaches for quitting smoking for that individual, noted Hilary Tindle, MD, MPH, associate professor of medicine, at Vanderbilt University.
Transcript
How can the NMR best be implemented into clinical care for nicotine and smoking treatments?
The NMR, or nicotine metabolite ratio, is not currently standard of care. Right now, if a patient comes into the doctor's office and wants to quit smoking or is goaded into quitting smoking, guilted into it by the provider, is motivated to quit, we don't typically use the nicotine metabolite ratio. It's just a conversation with a patient, sometimes their family, about all the options. So, nicotine replacement, varenicline, bupropion is another prescription medicine that is FDA approved for quitting. And then based on that conversation, the patient and the health care provider jointly make a decision [on] what's the best medicine.
The nicotine metabolite ratio is a precision approach that could actually inform what's the best medicine. Is it going to be varenicline? The faster metabolizers, people whose livers break down nicotine faster, tend to do better with varenicline; they quit twice as often on varenicline, also called Chantix, compared to the nicotine patch. So that's just one way that precision medicine can actually be folded into the current process of clinical care. But it's not standard of care yet.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
